Stable Cancer Patients Phase I Dosing Could Be Extended If Benefit Shown
Executive Summary
A Phase I trial participant should be allowed to continue receiving an investigational oncology compound beyond the duration of animal safety data if he has stable disease and he and his physician agree that this represents a benefit from therapy, FDA's Oncologic Drugs Advisory Committee said March 13